HSBC Holdings
CORT icon

HSBC Holdings’s Corcept Therapeutics CORT Stock Holding History

HSBC Holdings’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
15,623
+8,970
+135% +$542K ﹤0.01% 1775
2026
Q1 		$265K Buy
+6,653
New +$249K ﹤0.01% 2502
2025
Q4 		– Sell
-4,058
Closed -$338K – 2977
2025
Q3 		$338K Sell
4,058
-10,225
-72% -$740K ﹤0.01% 2283
2025
Q2 		$1.04M Sell
14,283
-14,385
-50% -$1.04M ﹤0.01% 1772
2025
Q1 		$3.01M Buy
28,668
+1,253
+5% +$76.3K ﹤0.01% 1294
2024
Q4 		$1.38M Sell
27,415
-26,988
-50% -$1.41M ﹤0.01% 1649
2024
Q3 		$2.56M Sell
54,403
-53,963
-50% -$1.92M ﹤0.01% 1346
2024
Q2 		$3.48M Buy
108,366
+27,785
+34% +$761K ﹤0.01% 1190
2024
Q1 		$2.03M Buy
80,581
+34,152
+74% +$807K ﹤0.01% 1464
2023
Q4 		$1.51M Buy
46,429
+20,360
+78% +$559K ﹤0.01% 1607
2023
Q3 		$707K Buy
26,069
+3,993
+18% +$116K ﹤0.01% 1850
2023
Q2 		$492K Sell
22,076
-659,002
-97% -$15.2M ﹤0.01% 1975
2023
Q1 		$14.8M Buy
681,078
+632,443
+1,300% +$13.9M 0.02% 705
2022
Q4 		$984K Buy
48,635
+15,153
+45% +$380K ﹤0.01% 1976
2022
Q3 		$872K Buy
33,482
+15,355
+85% +$411K ﹤0.01% 1892
2022
Q2 		$434K Sell
18,127
-3,358
-16% -$73.2K ﹤0.01% 2412
2022
Q1 		$484K Sell
21,485
-3,555
-14% -$75.6K ﹤0.01% 2442
2021
Q4 		$498K Buy
25,040
+9,042
+57% +$183K ﹤0.01% 2464
2021
Q3 		$316K Sell
15,998
-6,743
-30% -$141K ﹤0.01% 2514
2021
Q2 		$503K Buy
22,741
+7,065
+45% +$157K ﹤0.01% 2168
2021
Q1 		$376K Buy
15,676
+1,412
+10% +$37.7K ﹤0.01% 2168
2020
Q4 		$373K Buy
+14,264
New +$301K ﹤0.01% 2413
2019
Q4 		– Sell
-18,634
Closed -$263K – 3059
2019
Q3 		$263K Buy
+18,634
New +$229K ﹤0.01% 2716
2017
Q1 		– Sell
-12,868
Closed -$93K – 2202
2016
Q4 		$93K Buy
+12,868
New +$101K ﹤0.01% 2622

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HSBC Holdings's CORT Position: Q2 2026 in Review

HSBC Holdings increased its Corcept Therapeutics (CORT) stake by 135% in Q2 2026, buying an estimated $542K and bringing the position to 15,623 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

HSBC Holdings first reported a position in CORT in Q4 2016 and has held it in 24 quarters since. The position peaked at $14.8M in Q1 2023. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • HSBC Holdings held 15,623 shares of Corcept Therapeutics worth $1.38M as of Q2 2026.
  • HSBC Holdings bought 8,970 Corcept Therapeutics shares in Q2 2026, an estimated $542K.
  • Corcept Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #1775 holding.
  • HSBC Holdings first reported a position in Corcept Therapeutics in Q4 2016 and has held it in 24 quarters since.
  • HSBC Holdings's Corcept Therapeutics position peaked at $14.8M in Q1 2023.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.